An open label, balanced, randomized, two treatment, two-period, two-sequence, crossover, multicentric experimental comparative evaluation of two formulations of Quetiapine extended release tablets 400 mg under fasting conditions after multiple dose administration at steady state in adult schizophrenic patients stabilized on Quetiapine 400 mg per day.

Trial Profile

An open label, balanced, randomized, two treatment, two-period, two-sequence, crossover, multicentric experimental comparative evaluation of two formulations of Quetiapine extended release tablets 400 mg under fasting conditions after multiple dose administration at steady state in adult schizophrenic patients stabilized on Quetiapine 400 mg per day.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Schizophrenia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 02 Oct 2010 Status changed from not yet recruiting to completed as reported by Clinical Trials Registry - India record.
    • 09 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top